Beth-Ann Coller
A5075394578- Viral Infections and Vectors
- Viral Infections and Outbreaks Research
- Mosquito-borne diseases and control
- Malaria Research and Control
- SARS-CoV-2 and COVID-19 Research
- Virology and Viral Diseases
- COVID-19 epidemiological studies
- Global Security and Public Health
- Hepatitis B Virus Studies
- Influenza Virus Research Studies
- Vaccine Coverage and Hesitancy
- Insect symbiosis and bacterial influences
- vaccines and immunoinformatics approaches
- Pneumocystis jirovecii pneumonia detection and treatment
- Immune Cell Function and Interaction
- Pneumonia and Respiratory Infections
- Disaster Response and Management
- Dengue and Mosquito Control Research
- Animal Virus Infections Studies
- Immune responses and vaccinations
- Respiratory viral infections research
- Vibrio bacteria research studies
- Viral gastroenteritis research and epidemiology
- Immune Response and Inflammation
Merck & Co., Inc., Rahway, NJ, USA (United States)
2015-2025
Fundação de Medicina Tropical
2024
Fundação Oswaldo Cruz
2024
Universidade Federal de Minas Gerais
2024
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2024
Hawaii Biotech (United States)
2005-2013
United States Military Academy
2011-2013
BackgroundButantan–Dengue Vaccine (Butantan-DV) is an investigational, single-dose, live, attenuated, tetravalent vaccine against dengue disease, but data on its overall efficacy are needed.MethodsIn ongoing phase 3, double-blind trial in Brazil, we randomly assigned participants to receive Butantan-DV or placebo, with stratification according age (2 6 years, 7 17 and 18 59 years); 5 years of follow-up planned. The objectives the were evaluate symptomatic, virologically confirmed any...
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. A recent publication by V3SWG described attenuated, vesicular stomatitis virus (rVSV) as a chimeric vaccine for HIV-1 (Clarke et al., 2016). rVSV system is being explored platform development multiple This paper reviews molecular biological features system, followed template with details on against Zaire ebolavirus...
There is an unmet medical need for vaccines to prevent dengue. V180 investigational recombinant subunit vaccine that consists of truncated dengue envelope proteins (DEN-80E) all 4 serotypes. Three dosage levels the tetravalent DEN-80E antigens were assessed in a randomized, placebo-controlled, Phase I dose-escalation, first-in-human proof-of-principle trial healthy, flavivirus-naïve adults Australia (NCT01477580). The 9 formulations included either ISCOMATRIX™ adjuvant (2 levels),...
Abstract Background This double-blind study assessed immunogenicity, lot consistency, and safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVΔG-ZEBOV-GP). Methods Healthy adults (N = 1197) were randomized 2:2:2:2:1 to receive 1 3 consistency lots rVSVΔG-ZEBOV-GP (2 × 107 plaque-forming units [pfu]), high-dose 108 pfu, or placebo. Antibody responses pre-/postvaccination (28 days, 6 months; in a subset [n 566], months 12, 18, 24) measured....
Dengue (DENV) is a mosquito-borne virus with four serotypes causing substantial morbidity in tropical and subtropical areas worldwide. V181 an investigational, live, attenuated, quadrivalent dengue vaccine. In this phase 1 double-blind, placebo-controlled study, the safety, tolerability, immunogenicity of baseline flavivirus-naïve (BFN) flavivirus-experienced (BFE) healthy adults were evaluated two formulations: TV003 TV005. TV005 contains 10-fold higher DENV2 level than TV003. Two-hundred...
Recent Ebola outbreaks underscore the importance of continuous prevention and disease control efforts. Authorized vaccines include Merck's Ervebo (rVSV-ZEBOV) Johnson & Johnson's two-dose combination (Ad26.ZEBOV/MVA-BN-Filo). Here, in a five-year follow-up PREVAC randomized trial (NCT02876328), we report results immunology ancillary study trial. The primary endpoint is to evaluate long-term memory T-cell responses induced by three vaccine regimens: Ad26–MVA, rVSV, rVSV–booster....
The recombinant vesicular stomatitis virus-Zaire Ebolavirus envelope glycoprotein vaccine (rVSVΔG-ZEBOV-GP) was highly effective against Ebola virus disease in a ring vaccination trial conducted during the 2014–2016 outbreak Guinea and is licensed by regulatory agencies including US FDA, EMA, prequalified WHO. Vaccination studies nonhuman primate (NHP) model guided initial dose selection for clinical evaluation. We summarize two dose-ranging with clinical-grade rVSVΔG-ZEBOV-GP candidate to...
The rVSVΔG-ZEBOV-GP vaccine demonstrated efficacy in preventing Ebola virus (EBOV) disease a ring vaccination clinical trial conducted during the 2014–2016 West Africa outbreak and is licensed by regulatory agencies, including US FDA EMA. Here, we present two studies that evaluated durability of immunogenicity protection from an EBOV challenge up to ~12 months following with nonhuman primates (NHPs). Cynomolgus macaques were vaccinated either one or doses saline control challenged...
The 2013 Ebola epidemic in Central and West Africa heralded the emergence of wide-spread, highly pathogenic viruses. successful recombinant vector vaccine against (rVSVΔG-ZEBOV-GP) will limit future outbreaks, but identifying mechanisms protection is essential to protect most vulnerable. Vaccine-induced antibodies are key determinants efficacy, yet mechanism by which vaccine-induced prevent infection remains elusive. Here, we exploit a break long-term efficacy non-human primates identify...
Establishment of immune correlates protection can provide a measurable criterion for assessing against infection or disease. For some vaccines, such as the measles vaccine, antibodies serve correlate protection, but others, human papillomavirus, remains unknown. Merck & Co, Kenilworth, NJ, USA, in collaboration with multiple partners, developed live recombinant vesicular stomatitis virus vaccine (rVSVΔG-ZEBOV-GP [ERVEBO]) containing Zaire ebolavirus glycoprotein (GP) place GP to prevent...
The rVSVΔG-ZEBOV-GP vaccine (ERVEBO®) is a single-dose, live-attenuated, recombinant vesicular stomatitis virus indicated for the prevention of Ebola disease (EVD) caused by Zaire ebolavirus in individuals 12 months age and older.